INSUBCONTINENT EXCLUSIVE:
The Government Pharmaceutical Organisation (GPO) has prepared to register the affordable hepatitis C drug ravidasvir with the Food and
Drug Administration to improve access for 800,000 patients and reduce treatment costs.
